chronic lymphocytic leukemia


Also found in: Dictionary, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to chronic lymphocytic leukemia

chronic leukemia characterized by lymphoblast-like cells

Related Words

References in periodicals archive ?
A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
The submission of a supplemental New Drug Application (sNDA) for labeling is based on safety and efficacy results from the Phase III HELIOS (CLL3001) trial investigating the use of IMBRUVICA (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), added the company.
The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Chronic lymphocytic leukemia can result in marked immune dysfunction and immunodeficiency.
Global Markets Direct's, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline.
Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape.
M2 EQUITYBITES-September 15, 2015-AbbVie submits sNDA to US FDA for IMBRUVICA for treatment-naive chronic lymphocytic leukemia
M2 PHARMA-September 15, 2015-AbbVie submits sNDA to US FDA for IMBRUVICA for treatment-naive chronic lymphocytic leukemia
USPRwire, Mon Mar 16 2015] Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2015', provides an overview of the B-Cell Chronic Lymphocytic Leukemia's therapeutic pipeline.
Food and Drug Administration has approved Gazyva or GA101, a new monoclonal antibody, together with chlorambucil chemotherapy for the earlier untreated Chronic Lymphocytic Leukemia, said Genentech of the Roche Group (RHHBY).
Full browser ?